MENU
Showcases Stock ranks Forex

Ionis Pharmaceuticals (IONS)
43.35  -1.31 (-2.93%) 03-28 16:00
Open: 44.95 Pre. Close: 44.66
High: 44.95 Low: 43.32
Volume: 1,904,913 Market Cap: 6,318(M)
Stock Technical Analysis
Overall:     
Target: Six months: 52.96
One year: 55.67
Support: Support1: 41.60
Support2: 34.61
Resistance: Resistance1: 45.35
Resistance2: 47.66
Pivot: 43.12
Moving Averages: MA(5): 43.75
MA(20): 43.51
MA(100): 48.29
MA(250): 43.77
MACD: MACD(12,26): -0.80
Signal(12,26,9): -1.14
%K %D: %K(14,3): 63.71
%D(3): 61.26
RSI: RSI(14): 43.38
52-Week: High: 54.44
Low: 34.32
Change(%): 24.2
Average Vol(K): 3-Month: 1192
10-Days: 973
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 44.976 - 45.205 45.205 - 45.382
Low: 42.793 - 43.031 43.031 - 43.213
Close: 42.977 - 43.372 43.372 - 43.675
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ IONS ] has closed below upper band by 42.3%. Bollinger Bands are 39.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Stock chart
Stock News
Thu, 28 Mar 2024
ARK Investment Management LLC Reduces Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Thu, 28 Mar 2024
2024-03-28 | NDAQ:IONS | Press Release | Ionis Pharmaceuticals Inc - Stockhouse Publishing

Tue, 26 Mar 2024
Legato Capital Management LLC Takes $276000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Mon, 25 Mar 2024
Does Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Pay Compare Well With Peers? - Yahoo Movies Canada

Mon, 25 Mar 2024
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs? - Yahoo Finance

Fri, 22 Mar 2024
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Underperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 145.75
Shares Float (M) 144.53
% Held by Insiders 0.86
% Held by Institutions 100.94
Shares Short (K) 9110
Shares Short Prior Month (K) 8450
Stock Financials
EPS -2.560
Book Value (p.s.) 2.680
Profit Margin -46.50
Operating Margin 4.79
Return on Assets (ttm) -7.5
Return on Equity (ttm) -76.3
Qtrly Rev. Growth 113.6
Gross Profit (p.s.)
Sales Per Share 5.404
EBITDA (p.s.) -2.190
Qtrly Earnings Growth
Operating Cash Flow (M) -307.51
Levered Free Cash Flow (M) -159.99
Stock Valuation
PE Ratio -16.93
PEG Ratio 0.20
Price to Book value 16.18
Price to Sales 8.02
Price to Cash Flow -20.55
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android